Cuộc họp công bố kết quả kinh doanh Q2/2026 của Journey Medical (FBIO): Doanh thu tăng 23% khi Emrosi tăng tốc
Cuộc họp công bố kết quả tài chính quý 2/2026 của Journey Medical nhấn mạnh mức tăng trưởng doanh thu 23% lên 18,5 triệu USD, EBITDA điều chỉnh đạt mức dương và sự tăng tốc trong số lượng đơn thuốc Emrosi.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.